 |
|
Safety of Antiplatelet Therapy Prior to Intravenous Thrombolysis in Acute Ischemic Stroke
Maarten Uyttenboogaart, MD;
Marcus W. Koch, MD;
Karen Koopman, MD;
Patrick C. A. J. Vroomen, MD, PhD;
Jacques De Keyser, MD, PhD;
Gert-Jan Luijckx, MD, PhD
Arch Neurol. 2008;65(5):607-611. Published online March 10, 2008 (doi:10.1001/archneur.65.5.noc70077).
Background There is some uncertainty whether prior use of antiplatelet (AP) drugs increases the risk of symptomatic intracerebral hemorrhage (SICH) and influences functional outcome in patients with ischemic stroke treated with intravenous thrombolysis.
Objective To assess whether prior use of AP drugs is related to outcome following intravenous tissue plasminogen activator therapy in patients with ischemic stroke.
Design, Setting, and Patients A single-center prospective observational cohort study of the relation between prior AP therapy, occurrence of SICH, and functional outcome of consecutive patients with ischemic stroke undergoing intravenous thrombolysis with tissue plasminogen activator in a university hospital between April 1, 2002, and November 30, 2006.
Main Outcome Measures The occurrence of SICH and favorable outcome reflecting independence defined as a modified Rankin Scale score of 2 or lower at 3 months.
Results Of the 301 patients who received intravenous tissue plasminogen activator, 89 used AP drugs prior to thrombolysis. Symptomatic intracerebral hemorrhage occurred in 12 patients (13.5%; 95% confidence interval, 7.8%-22.3%) who had received AP drugs and in 6 patients (2.8%; 95% confidence interval, 1.2%-6.2%) without prior AP therapy (P = .001). Multivariate analysis revealed that prior AP therapy was an independent predictor of SICH (odds ratio, 6.0; 95% confidence interval, 2.0-17.1). Nonetheless, prior AP therapy was independently associated with a favorable outcome (odds ratio, 2.0; 95% confidence interval, 1.0-4.3).
Conclusion Despite a higher incidence of SICH, the net benefit of intravenous tissue plasminogen activator therapy for acute ischemic stroke was greater in patients using AP drugs.
Author Affiliations: Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
This Month in Archives of Neurology
Arch Neurol. 2008;65(5):572-573.
FULL TEXT
Antiplatelet Therapy and the Risk of Intracranial Hemorrhage After Intravenous Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke
Hen Hallevi and James C. Grotta
Arch Neurol. 2008;65(5):575-576.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Factors Associated With Intracerebral Hemorrhage After Thrombolytic Therapy for Ischemic Stroke: Pooled Analysis of Placebo Data From the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials
Cucchiara et al.
Stroke 2009;40:3067-3072.
ABSTRACT
| FULL TEXT
Outcomes of Intravenous Recombinant Tissue Plasminogen Activator Therapy According to Gender: A Clinical Registry Study and Systematic Review
Meseguer et al.
Stroke 2009;40:2104-2110.
ABSTRACT
| FULL TEXT
Advances in Emerging Therapies
Higgins and Lees
Stroke 2009;40:e292-e294.
FULL TEXT
Is Thrombolysis Safe in Patients Taking Antiplatelet Agents?
JWatch Neurology 2008;2008:1-1.
FULL TEXT
Antiplatelet Therapy and the Risk of Intracranial Hemorrhage After Intravenous Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke
Hallevi and Grotta
Arch Neurol 2008;65:575-576.
FULL TEXT
|
